论文部分内容阅读
为了探讨血清ｓＩＬ２Ｒ的表达水平与非小细胞肺癌患者病期和预后的关系，作者采用酶标双抗体夹心法，对３０例非小细胞肺癌患者手术前、术后１０天和术后３０天血清ｓＩＬ２Ｒ表达水平进行了动态研究。结果表明，非小细胞肺癌患者ｓＩＬ２Ｒ表达水平明显高于正常人（Ｐ＜０．０１），未复发组患者术后的ｓＩＬ２Ｒ表达水平呈现一个暂时性增高到逐渐下降近正常，表明其术后免疫功能从暂时抑制到逐渐恢复的过程。复发组的患者术后ｓＩＬ２Ｒ表达水平持续居高不下，表明其术后免疫功能持续低下。未复发组与复发组比较Ｐ＜０．００１，提示ｓＩＬ２Ｒ表达水平与非小细胞肺癌患者的病期和预后有密切关系。
To explore the relationship between serum sIL-2R expression and the stage and prognosis of patients with non-small cell lung cancer, the authors used enzyme-labeled double antibody sandwich method to preoperatively, postoperatively 10 days, and postoperatively 30 cases for 30 patients with NSCLC. The serum level of sIL-2R was dynamically studied. The results showed that the expression level of sIL-2R was significantly higher in non-small cell lung cancer patients than in normal controls (P<0.01). The expression level of sIL-2R in non-recurrent patients showed a temporary increase to a gradual decline near normal, indicating that Its postoperative immune function is temporarily suppressed and gradually restored. The expression level of sIL-2R in patients with relapsed group continued to remain high, indicating that the postoperative immunological function continued to be low. P<0.001 in non-recurrent group and recurrent group, suggesting that the expression level of sIL-2R is closely related to the stage and prognosis of patients with non-small cell lung cancer.